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In the present paper, we analyze the cell number within lamina X at the end stage of disease in a G93A mouse model of ALS; the
effects induced by lithium; the stem-cell like phenotype of lamina X cells during ALS; the differentiation of these cells towards
either a glial or neuronal phenotype. In summary we found that G93A mouse model of ALS produces an increase in lamina
X cells which is further augmented by lithium administration. In the absence of lithium these nestin positive stem-like cells
preferentially differentiate into glia (GFAP positive), while in the presence of lithium these cells differentiate towards a neuron-
like phenotype (𝛽III-tubulin, NeuN, and calbindin-D28K positive). These effects of lithium are observed concomitantly with
attenuation in disease progression and are reminiscent of neurogenetic effects induced by lithium in the subependymal ventricular
zone of the hippocampus.
1. Introduction
Plastic changes were described in the spinal cord in the
course of amyotrophic lateral sclerosis [1, 2]. These consist
of various morphological effects involving both resident cells
such as neurons and glia and nonresident inflammatory
cells. Among plastic effects, the sprouting of axon collaterals
from spared motor neuron at the level of the peripheral
muscles is well described [3, 4]. This is consistent during the
disease course and it represents a marker of disease when it
is detected by using electromyography. On the other hand,
neuronal plasticity involving the motor neuron cell body in
the ventral horn of the spinal cord represents a critical issue,
and it is a hot topic in ALS research. In detail, the lack of
effective neurogenesis in the course of ALS provided the
basis to plan stem cell transplantation in humans either to
substitute or prolong the survival of spared motor neurons
[5, 6]. In keeping with stem cells, only a few studies focused
on the occurrence of adult stem cells in ALS spinal cord.
These studies documented the occurrence of increased cell
proliferation during experimental models of spinal cord
disease, mostly following traumatic spinal cord injury ([7]
for a comprehensive review). Only a few studies analyzed
endogenous spinal cord stem cells during ALS [8–11] and
being the most recent studies rather focused on detailing the
transplantation of exogenous stem cells previously induced
to differentiate towards a neuron-like phenotype [12–16].
In fact, despite the fact that spinal cord disorders increase
proliferation of neural progenitor cells (NPC), these gen-
erate preferentially glial cells instead of neurons [9, 10, 17]
according to the concept that spinal cord environment has
a strong gliogenic influence [7]. Thus, in order to address
NPC proliferation towards a neuronal phenotype, further
stimuli in the course of the disease need to be provided.
It is well known that adult stem cells in both humans and
various animal species in vivo are induced to proliferate and
differentiate following lithium administration. This effect is
well established in the subependymal ventricular zone (SVZ)
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of the lateral ventricles where lithium dramatically increases
the amount of neurogenesis towards a specific calbindin-
D28K neuronal phenotype [18]. In previous studies we found
that lithium increases the amount of calbindin-D28Kpositive
cells in the ventral horn of the spinal cord of G93A mice
[19, 20]. Most of these calbindin-D28K positive cells costain
for BrdU [19–21]. Adult stem cells in the spinal cord appear
in the ependymal (and subependymal) zone within lamina
X. In fact, as scholarly reviewed by Sabelstro¨m et al. [7],
studies based on mapping the genetic fate and isolation by
flow cytometry indicate that ependymal cells in the adult
spinal cord own stem cell potential [22–24].
Therefore, in the present study, we analyzed lamina X
around the central canal including the ependymal layerwhich
possesses stem cell-like activity inG93Amice with or without
chronic lithium administration.
In detail, we measured the number of lamina X cells as
well as the presence of specific phenotypes such as nestin,
GFAP, 𝛽III-tubulin, NeuN, and calbindin-D28K. These cell
counts were carried out at the terminal disease stage when the
occurrence of protective effects by lithium was documented
as both increased survival and motor performance.
2. Materials and Methods
2.1. Animals. Male B6SJL-TgN(SOD1-G93A)1Gur mice,
expressing the human G93A Cu/Zn superoxide dismutase
1 (SOD1) mutation (𝑛 = 10) and related wild type (WT)
littermates (𝑛 = 10) were purchased from the Jackson Labo-
ratory (Bar Harbor, ME, USA) via Charles River (Calco, LC,
Italy). Mice received food and water ad libitum and were
housed under controlled conditions: 12 hours light/dark
cycle and at 21∘C room temperature.
2.2. Experimental Groups and Treatments. Transgenic G93A
superoxide dysmutase 1 (SOD) mice and their wild type
(WT) littermates were divided into four experimental groups:
lithium-treatedG93Amice (𝑛 = 5); saline-treatedG93Amice
(𝑛 = 5); lithium-treated WT mice (𝑛 = 5); saline-treated
WT mice (𝑛 = 5). Lithium chloride (Sigma, St. Louis, MO,
USA) was administered (to both G93A and WT mice) every
other day at the dose of 1mEq/Kg i.p. dissolved in saline
(sodium chloride 0.9%) in a volume of 200𝜇L. Controls (both
G93A and WT mice) received an equal volume of saline. All
treatmentswere carried out in themorning, between 9.00 and
12.00 am. Lithium was administered starting at 67 days of
age until the end point of disease. In order to avoid arbitrary
assumptions we specifically considered “end point” the time
point when the mouse was no longer able to right itself from
a sided position during a 30-second time interval (due to
a severe palsy of all limbs), according to Parone et al. [26].
Survival was considered until this end point and it was plotted
as a Kaplan-Meier curve.When the genetic disease eventually
led to the end point each mouse was sacrificed in order to
avoid discomfort due to impaired feeding, drinking, and, as
originally reported [27], also breathing. Sacrifice occurred
by using deep chloral hydrate anaesthesia while perfusing
the mouse to preserve the spinal cord for light microscopy.
All experiments were carried out in compliance with the
European Council directive (86/609/EEC) for the use and
care of laboratory animals.
2.3. Behavior. Each behavioral test was carried out by gently
handling each mouse. All motor tests began at 60 days of age,
one week before starting chronic lithium administrations,
and they were performed weekly for all animal groups (𝑛 = 5
per group). Locomotor activity, motor strength, and motor
coordination were evaluated as described in previous works
[19, 28] by using stride length test, paw grip endurance
(PaGE) test, and rotarod test, respectively. Each test was
scored blindly.
2.4. Stride Length Test. The stride length was measured
following the method by Fernagut et al. [29] which was
further modified by Fulceri et al. [30]. Briefly, the apparatus
was included into an open field (80× 80× 30 cm). In this open
field a runway wide illuminated (75 × 5 cm) was leading into
a dark box (20 × 15 × 10 cm). Each mouse was allowed to run
on the bright runway towards the dark box.The hind paws of
each mouse were ink-painted and the distance between two
paw prints was counted as the stride length.The three longest
stride lengths were selected from each test. Data are reported
as the mean of these stride lengths. Mice unable to walk were
scored zero.
2.5. Paw Grip Endurance (PaGE) Test. The PaGE test was
used to assess the motor strength as reported originally by
Weydt et al. [31]. Each mouse was placed over a meshed
wire grid, which was shaken to force the mouse to grip the
grid. Then the grid was gently turned upside down and the
latency until a mouse was able to keep the hold was recorded
with a cutoff time of 90 seconds. Each mouse was scored for
three consecutive trials and the longest latency was recorded.
Animals unable to grip the grid were scored zero.
2.6. Rotarod Test. Motor coordination was evaluated by a
rotating rod.The rodwas automatically rotating at 15 rpm and
the time during which the mouse was able to stay on the rod
during a 10-minute (600 seconds) interval was recorded. The
best result of three trials was recorded for each mouse.
All behavioral data are expressed as the mean ± SEM
from each group for each unit of measurement, which was
used in each test. When showing the data we plotted only the
symptomatic groups ofmice (G93A) treatedwith either saline
or lithium. Inferential statistics were applied comparing these
two groups of mice using 𝑡-test for continuous values with
normal distribution. The null hypothesis𝐻
0
was rejected for
𝑃 ≤ 0.05.
As an additional validation of inferential statistics, motor
behavior, apart from using ANOVA, was also compared by
using the mixed model ANOVA for repeated measures.
2.7. Morphology. When the end point was manifested, mice
received deep chloral hydrate anesthesia.They were perfused
transcardially by using a fixing solution composed of 150mL
4% paraformaldehyde in PBS 0.1 N, pH 7.3, which was
delivered by a peristaltic pump after washing with 50mL of
saline. After perfusion, the whole mice column was dissected
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Figure 1: Effects of lithium on survival and motor performance in G93A mice. The graphs report data from G93A mice with either saline
or lithium. Lithium prolongs mice survival as shown by Kaplan-Meier survival curve. Lithium counteracts motor deterioration measured by
stride length, paw grip endurance (PaGE), and rotarod. Values are given as the mean ± SEM. ∗𝑃 ≤ 0.05 compared with mice administered
saline.
and moved overnight to a solution of 4% paraformaldehyde
for 24 h at 4∘C. The spinal cord was carefully dissected from
the column. From each mouse, a few mm piece from the
lower lumbosacral tract of the cord was isolated to be further
processed for semithin sections.
2.8. Light Microscopy. The spinal cord, except the small
sample for semithin sections and further ultrastructural
studies, was washed out in PBS and transferred into 70%
alcohol solution at 4∘C. All samples were dehydrated by
increasing alcohol solutions, immersed in xylene for several
hours, and finally embedded in paraffin. Seven 𝜇m thick
microtome transverse sections were collected serially. The
thickness of the slices was planned to count two cell sizes
roughly distinguishable around the central canal and within
lamina X. This stereological-like procedure follows what
previously was published to adapt cell count to heterogeneity
of cell size of a given region [28], which was adapted here
to the lamina X of the spinal cord. In detail, to identify
lamina X, we used a mouse spinal cord atlas [25] referring
to lumbar plates where the count was eventually carried out.
We found that within lumbar lamina X including the central
canal two predominant cell sizes ranging around 7 𝜇m and
20𝜇m can be described. This preliminary evaluation of the
cell diameters was determined at 40x magnification, using
software for image analysis. When counting larger cells we
measured the number of lamina X cells in one out of four
sections, to provide a space interval of about 30 𝜇m. On the
other hand, ependymal cells, with a smaller diameter (6-
7 𝜇m), were counted in one out of two sections, to provide a
space interval of about 14 𝜇m. A total of 400 sections/mouse
per group were counted. Different cell sizes were cumulated
in the final count. These counts globally refer to a tract of the
lumbar cord 1.5 cm long.
Slices were stained with haematoxylin and Eosin (H&E)
or against various antigens by using immunohistochemistry
counterstained with haematoxylin (or DAPI for immunoflu-
orescence).
Counts represent the number of cells counted in 1.5 cm
of the lumbar cord and are expressed as the mean ± SEM
for each group. Cell counts were performed by at least
two different observers, unaware of treatments. Comparisons
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Figure 2: Pilot lightmicroscopy procedures showing semithin sections. For identification of lamina X and ependymal area, 1-2 𝜇m thick serial
sections, obtained with a porter blumMT-1 or an ultramicrotome, were stained with 1% toluidine blue and 1% methylene blue in 1% sodium
tetraborate and observed under light microscopy. In each experimental group (wild type administered saline,WT Sal; wild type administered
lithium, WT Li; transgenic SOD1 G93A mice administered saline, G93A Sal; transgenic SOD1 G93A mice administered lithium, G93A Li)
the central canal is limited by densely packed cells with polymorphic nuclei, which increase their number and appear as multiple call layers
in G93A mice compared with WT. Again, in G93A mice, the staining is consistently more intense compared with WT. Scale bar = 21𝜇m.
between groups were made by using a one-way analysis of
variance ANOVA combined with Scheffe` post hoc tests. Null
hypothesis was rejected for 𝑃 ≤ 0.05.
2.9. Immunohistochemistry. We used primary antibodies
against nestin for undifferentiated, stem-like cells, the glial
fibrillary acidic protein (GFAP), the early neuronal marker
𝛽III-tubulin, and the late neuronal marker NeuN. We also
used primary antibodies against calbindin-D28K since this
antigen is strongly expressed in the CNS during lithium-
induced differentiation of neural progenitor cells [18–20, 32].
Slices were dewaxed by xylene, rehydrated by decreasing
alcohol solutions, and permeabilized by Triton X 0.1% in PBS.
For immunoperoxidase, slices were preincubated with
3% hydrogen peroxide for 30 minutes to inhibit the activ-
ity of the endogenous peroxidases followed by a blocking
solution (10% normal goat serum in PBS) for 1 hour at
room temperature. Primary antibody solutions were pre-
pared in PBS containing 2% normal goat serum and they
were incubated overnight at 4∘C. Primary antibodies were
used at the following concentrations:mouse anti-𝛽III-tubulin
(1 : 50, Millipore, Billerica, MA, USA), mouse anti-GFAP
(1 : 400, Sigma), mouse anti-NeuN (1 : 50, Millipore), and
mouse anticalbindin-D28K (1 : 100, Sigma).The reactionwith
primary antibody was revealed by anti-mouse biotinylated
secondary antibody (Vector Laboratories, Burlingame, CA,
USA) which was used at a dilution of 1 : 200, for 1 hour,
at room temperature. This was followed by incubation with
avidin-biotin kit (Vector Laboratories), for 1 hour, at room
temperature. The binding was revealed by using the perox-
idase substrate diaminobenzidine (Vector Laboratories) for
1-2 minutes. All sections, except those labelled with anti-
NeuN and anti-nestin antibodies, were counterstained with
haematoxylin. Finally, sections were dehydrated by increas-
ing alcohol solutions, clarified in xylene, and coverslipped
with the mounting agent DPX (Sigma).
For the immunofluorescence slices were exposed to a
mouse anti-nestin (1 : 200, Abcam, Cambridge, UK) primary
antibody which was further revealed by using the anti-mouse
fluorescent secondary antibody Alexa Fluor 488 (1 : 200,
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Figure 3: Nestin immunostaining within lamina X. Representative pictures are reported in (a) showing that lamina X shows neglectable
nestin-immunofluorescence in WT mice (both WT Sal or WT Li). In contrast, nestin immunostaining is well evident within the lamina X
from ALS mice (both G93A Sal and G93A Li). In particular, in G93A mice treated with saline nestin-positive fibers between the ependymal
cells appear to project from the ependymal canal into lamina X, where only a few cells appear labelled. In contrast, in G93A mice treated
with lithium nestin immunofluorescence is dramatic and involves both the ependymal cells and stem-like cells within the entire lamina X
(arrows). (b) The graph reports the count of nestin-positive cells in both lamina X and ependymal canal. ∗𝑃 ≤ 0.05 compared with other
groups. Scale bar = 26 𝜇m.
Life Technologies, Carlsbad, CA, USA). After washing in
PBS, slices were coverslipped with Fluoroshield (Sigma). The
nuclear dye DAPI (1 : 1000) (Sigma) was added to the solution
to visualize cell nuclei. DAPI- and nestin-stained pictures
were merged.
All stained slices were observed using a Nikon Eclipse 80i
light microscope equipped with digital camera and software
for image analysis.
2.10. Semithin Sections. In order to provide detailed represen-
tative images of ependymal cells we carried out semithin sec-
tions which were also used as a reference for further electron
microscopy studies. Briefly, samples from lower lumbosacral
segments previously fixed overnight 4% paraformaldehyde
were dissected from spinal cord and switched to a 2%
paraformaldehyde/0.1% glutaraldehyde in 0.1 N PBS, pH 7.4,
for 90min at 4∘C. After washing samples were postfixed in
1% OsO
4
in PBS, dehydrated in ethanol, and embedded in
Epon-araldite. For identification of lamina X and ependymal
area, 1-2 𝜇m thick serial sections, obtained with a porter
blumMT-1 or an ultramicrotomeReichert-Jung, were stained
with 1% toluidine blue and 1% methylene blue in 1% sodium
tetraborate and observed under light microscopy.
3. Results and Discussion
3.1. Survival and Behaviour. As firmly established the G93A
mutation of SOD1 led to a rapidly progressing palsy which
was lethal in a few weeks after symptoms onset (Figure 1).
As previously reported [19, 20, 28, 33, 34], chronic lithium
administration prolonged significantly the survival as shown
in the Kaplan-Meier curve (Figure 1), while it improved
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Figure 4: H&E staining of lamina X. (a) Atlas plate [25] of the lumbar cord (L
4
) used as the reference for representative pictures. (b)
Representative high magnification of H&E stained pictures showing L
4
lamina X, treated with either saline or lithium. The cell number
counted within lamina X is equivalent for WT mice treated with either saline (WT Sal) or lithium (WT Li). On the other hand, the cell
number is increased in the lamina X of G93A mice treated with saline (G93A Sal) or lithium (G93A Li). When counting the cell number it is
evident that, as reported in the histogram (c), the cell number in lamina X is mostly increased in G93A mice receiving lithium. The increase
in the cell number occurring within lamina X of G93A mice is better visualized at the level of the ependymal layer. Dashed lines draw the
border of the lamina X. ∗𝑃 ≤ 0.05 compared with other groups. Scale bar = 30𝜇m.
motor performance of G93A mice in all the motor tests
(Figure 1). The behavioral deterioration and death were not
abolished by lithium. Lithium was delaying the motor deteri-
oration and prolonging the lifespan of the mice. These effects
are evident more at the beginning compared with the end
stage of disease, when these effects were no longer detectable.
When we implemented statistical analysis by using mixed
model ANOVA for repeatedmeasures the protective effects of
lithium on the decay of motor activity remain significant for
a large part of the disease duration, but they were no longer
significant in the last week before the end stage of disease
(stride length and rotarod).
Protective effects of lithium in motor neuron disorders
are documented in a variety of experimental conditions
[19, 20, 28, 33–37]. Similarly, it was shown that lithium
protects against neurotoxicity to peripheral axons [38, 39].
Nonetheless, a lack of effects of lithium in the G93A mouse
model was also reported [40]. The discrepancy brought by
this latter study may due to the fact that, for unknown
reasons, authors did not administer lithium at levels required
to produce its pharmacological effects such as autophagy
induction [41]. As reported by Chiu et al. [42], it is
likely that this depends on lithium concentrations achieved
by Pizzasegola et al. [40] which are way below (at least
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Figure 5: Representative pictures from hemi-lumbar cord. Representative pictures of H&E stained hemi-lumbar cord. In the upper lane are
reported pictures from wild type mice treated with either saline (WT Sal) or lithium (WT Li). In the lower lane are reported G93A mice
treated with either saline (G93A Sal) or lithium (G93A Li). Pictures are representative of end stage of disease. Noteworthy is the generalized
increase in spinal cord cell density which is produced by lithium administration in G93A mice. Such an effect appears to extend in the whole
grey matter. Scale bar = 232𝜇m.
10 fold) those required to produce any pharmacological
effect.
In the present study, in experimental conditions where
lithium did provide neuroprotection, we analyzed the plastic
effects induced by chronic lithium administration within
lamina X.
3.2. Plasticitywithin LaminaX of the Spinal Cord duringMotor
Neuron Disease with or without Lithium Administration.
Figure 2 shows increased basophilic cell density around the
central canal, which occurs selectively in G93A mice. This is
in line with increased mitosis occurring in ALS spinal cord
reported by Chi et al. [8]. Spinal cord plasticity based on
stem cells proliferation within adult spinal cord is a hot topic
under intense investigation, in relationship with both spinal
cord injury and degenerative motor neuron disorders. A very
recent state-of-the-art review [7] clearly indicated that, within
spinal cord, adult stem cells originate from the ependymal
layer within lamina X. This is based on genetic studies
mapping the fate of these cells along with flow cytometric
characterization [7, 22–24]. In baseline conditions stem cells
from the spinal cord are rarely mitotic, while they increase
dramatically their mitosis following injuries. These data are
confirmed here by staining the stem cell antigen nestin.
This was neglectable in WT, while it increased markedly in
G93A mice. Noticeably, when G93A mice were administered
with lithium nestin immunopostive cells further increased,
as shown in Figure 3. This increased mitogenic activity in
lamina X was confirmed by plain cell count following H&E
staining as reported in Figure 4.Most of the studies analyzing
spinal cord stem cells in disease states were focused on
traumatic or other acute spinal cord injuries (for a review
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Figure 6: GFAP immunostaining within lamina X. Representative high magnification of GFAP immunostained slices from lamina X of
lumbar spinal cord (a). The cell number counted within lamina X is equivalent for WT mice treated with either saline (WT Sal) or lithium
(WT Li). On the other hand, the cell number is dramatically increased in the lamina X of G93Amice treated with saline (G93A Sal), while it is
suppressed in G93A mice treated with lithium (G93A Li) as reported in the histogram (b). In general, GFAP immunostaining shows positive
cells on external side of the ependymal layer, while in G93A Sal intense immunostaining extends in the surrounding lamina X. ∗𝑃 ≤ 0.05
compared with other groups. Scale bar = 30𝜇m.
[7]), while only a few studies were carried out in the course
of ALS. In line with the literature describing the stem cells
fate following spinal cord injuries we already described a
general increase in cell density in the lamina VII of spinal
cord of ALS mice along with increase in BrdU staining [19,
20]. In the present study we counted an increased number
of stem-like cells within lamina X of G93A mice (Figure 3)
and a general increase in cell number in the same region
of ALS mice (Figure 4). This occurs more abundantly in
G93A mice treated with lithium as evident in representative
Figure 4(b) and as reported in the counts of Figure 4(c).
Moreover, when examining at low magnification the hemi-
spinal cord from G93A mice a generalized increase in cell
density is evident which also extends to the entire dorsal
horn (Figure 5). The increase in stem-like cells and total cell
number we measured in the lamina X is in line with the
increase in NPC previously reported in ALS mice [8]. Such
an increase (both for stem-like cells, Figures 3(a) and 3(b),
and total cells, Figures 4(b) and 4(c), resp.) is more evident
when G93A mice were administered with lithium. Lithium
alone, administered to WT mice, did not increase neither
nestin-positive cells nor total cell number. In the paper by
Chi and collaborators [8] it was described that most of the
NPC occurring in the ALS spinal cord differentiate towards
glia, which is the case also following spinal cord injury [7].
In fact, in the present study, we found a dramatic increase in
GFAP immunopositive cells in the lamina X of G93A mice
administered with saline (Figures 6(a) and 6(b)). In sharp
contrast, the amount of GFAP positive cells in G93A mice
administered with lithium were suppressed even compared
with controls (Figures 6(a) and 6(b)). These latter findings
brake the concept of the gliogenetic fate of stem cells in
the spinal cord. So far, increased expression of GFAP occurs
constantly when spinal cord stem-like cells are proliferating
following either spinal cord injuries [7, 23] or ALS [8]. In
sharp contrast, in the present study, we documented that,
in G93A mice, chronic lithium administration produces a
dramatic increase in nestin immunostaining but suppresses
BioMed Research International 9
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Figure 7: 𝛽III-tubulin immunostaining within lamina X. Representative high magnification of 𝛽III-tubulin immunostained slices from
lamina X of lumbar spinal cord (a).The cell number counted within lamina X is equivalent forWTmice treated with either saline (WT Sal) or
lithium (WT Li). On the other hand, the cell number is dramatically increased in the lamina X of G93Amice treated with lithium (G93A Li),
while it is suppressed in G93Amice treated with saline (G93A Sal) as reported in the histogram (b). In general, 𝛽III-tubulin immunostaining
shows an opposite pattern compared with GFAP (see Figure 6). Following lithium administration an intense immunostaining is visible
throughout the whole lamina X of G93A mice. ∗𝑃 ≤ 0.05 compared with other groups. Scale bar = 30𝜇m.
GFAP immunostaining (Figures 3 and 6, resp.). Such a switch
in cell differentiation is further substantiated by the dramatic
increase in early and late neuronal markers 𝛽III-tubulin
(Figures 7(a) and 7(b)) and NeuN (Figures 8(a) and 8(b))
occurring when lithium was administered to G93A mice.
This is opposite to what occurred in saline administered
ALS mice owing to increased GFAP positive cells with no
increase in neuronal markers within lamina X (𝛽III-tubulin,
Figures 7(a) and 7(b), andNeuN, Figures 8(a) and 8(b)).Thus,
the gliogenic effects which routinely characterize increased
nestin-positive cells in the diseased spinal cord were reversed
here by chronic lithium administration, which increases
neuronal markers while suppressing GFAP positive cells. In
WT mice lithium did not produce any noticeable change in
nestin, GFAP, 𝛽III-tubulin, or NeuN immunostaining. This
is in line with the concept that proliferation of ependymal
cells in the spinal cord is scarce in baseline conditions. Only
spinal cord injury [23, 43, 44] or degenerative disorders [8, 19]
produce a stimulation of neurogenesis in the ependymal zone
of lamina X. Lithium magnifies such an effect by further
increasing cell number and, most importantly, addressing
their differentiation towards a neuron-like phenotype while
inhibiting gliogenesis. These effects were described following
adult spinal cord injury, and now they extend to a chronic
model of motor neuron disorder.
In fact, by using the G93A mouse model of ALS, here
we provide specific evidence that lithium increases total
cell number in the lamina X of the spinal cord (Figure 4),
thus confirming previous experimental observations [20].
In detail, in the present paper, we found that the disease
itself increases the cell number within lamina X of the
spinal cord (Figure 4). This effect is magnified by lithium
administration, only in G93Amice (Figure 4). When lithium
was administered to WT no increase in the total lamina X
cell number was observed (Figure 4). Interestingly, this con-
firms what previously reported [8] showing a compensatory
10 BioMed Research International
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Figure 8: NeuN immunostaining within lamina X. Representative high magnification of NeuN immunostained slices from lamina X of
lumbar spinal cord (a). Again, immunopositive cells within lamina X for WT mice treated with either saline or lithium (WT Sal or WT Li,
resp.) is equivalent. On the other hand, NeuN positive cells are suppressed in the lamina X of saline treated G93A mice (G93A Sal), while
lithium administration (G93A Li) partially recovers NeuN immunostaining as reported in the histogram (b). ∗𝑃 ≤ 0.05 compared with other
groups. Scale bar = 30𝜇m.
activation of neurogenesis in the spinal cord during ALS.
Such a confirmation was directly measured in the present
work by counting the number of nestin-positive cells
(Figure 3). However this neurogenetic effect is routinely
expected to lead to glia [8]. This was also confirmed in
the present work, where in G93A mice administered with
saline an increase in GFAP positive cell number was detected
within lamina X (Figure 6). However, this was reversed by
the administration of lithium, which suppressed the number
of GFAP positive cells (Figure 6) while markedly increasing
the number of positive cells for the early or late neuronal
marker 𝛽III-tubulin (Figure 7) and NeuN (Figure 8) in G93A
mice. In detail, while increased cell number occurs in the
lamina X of G93A mice independently by the administration
of lithium, it is just the presence of lithium which addresses
these cells towards a neuron-like phenotype instead of glia.
This effect reminds what it is well established for the effects of
lithium in the hippocampus and SVZ where it induces neu-
rogenesis while inhibiting glial differentiation and promoting
neuronal differentiation [18, 45–56]. In fact, it is well known
that lithium in the hippocampus specifically induces the
occurrence of calbindin-D28K positive neuron-like cells [18].
Remarkably, we found here that even in the spinal cord
lamina X lithium promotes the increase of calbindin-D28K
positive neurons, which occurs in both G93A mice and WT
(Figure 9).
Lamina X is known to be a niche for stem cells in the
adult spinal cord [57]. In our hands such a niche appears to be
“lazy” meaning that it is dormient in baseline conditions and
it reacts with cell proliferation without neuronal differentia-
tion in disease conditions.The concomitant administration of
lithium in disease conditions enhances cell proliferation and
addresses them towards a neuron-like phenotype.The occur-
rence of proliferating nestin-positive stem-like cells described
here confirms the occurrence of actual cell mitosis following
lithium in ALS spinal cord which we already described
by merged BrdU and calbindin-D28K immunostaining
[19].
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Figure 9: Calbindin-D28K immunostaining within lamina X. Representative highmagnification of calbindin-D28K immunostaining within
lamina X of lumbar spinal cord (a). In general, intense calbindin-D28K immunopositivity appears to be localized in the ependymal layer.
The cell number counted within lamina X is markedly increased by lithium in both WT and G93A mice (WT Li and G93A Li, resp.). On the
other hand, the cell number is reduced in G93A mice administered saline (G93A Sal). This latter effect is particularly evident in the area of
lamina X external to the ependymal canal. In this area only pale cell shapes avoided from the count are visible, which explains the very low
cell number reported in the histogram (b). In G93A mice the effects of lithium extend the strong immunostaining to the entire lamina X.
∗𝑃 ≤ 0.05 compared with other groups. Scale bar = 36 𝜇m.
It is interesting that lithium administration needs to be
carried out in G93A mice in order to produce an increase in
neurogenesis and neuronal differentiation in the spinal cord.
In fact, lithium by itself does not produce any increase in the
number of nestin-,𝛽III-tubulin-, andNeuN-immunopositive
cells. Moreover, even the number of H&E stained cells
does not increase in WT mice administered with lithium.
In contrast, lithium alone (in WT mice) is sufficient to
increase the number of calbindin-D28K positive cells. This
suggests that this specific effect may be the consequence of
a mere phenotypic shift. This hypothesis is consistent with
the increase of calbindin-D28K positive cells which wasmore
marked compared with BrdU positive cells in the spinal cord
of G93A mice [19].
The activation of the spinal cord ependymal niche is
recently described by other authors [57] who found a pattern
of radial nestin immunostaining occurring after a variety of
disorders of the spinal cord which is reminiscent of what
we observed in representative pictures (Figure 3(a)). In line
with these studies we found that nestin immunopositive cells
possess radial processes and, as happening after spinal cord
injury, they are more abundant in the lateral aspects of the
canal. Altogether, these data provide novel evidence onplastic
phenomena detectable at the level of the spinal cord niche
in the lamina X during an ALS model and substantiate the
modulatory effects of lithium on these phenomena. It is
exciting that these data replicatewhatwas already foundmore
profusely for the effects of lithium in the telencephalon at
the level of SVZ. Again, these data extend to amyotrophic
lateral sclerosis which was previously reported following
spinal cord injury [52, 58] showing the prosurvival effects
produced by lithium administration for the neuron-like stem
cells either autonomous or implanted in the damaged cord.
This might explain very recent data confirming the neuro-
protective effects of lithium also against spinal cord injury
[59].
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4. Conclusions
The present experimental work, apart from providing a con-
firmation of the protective effects of lithium in the course of
the G93Amousemodel of ALS, it shed new lights on the plas-
tic phenomena ongoing in this experimental model of motor
neuron disease and their modulation induced by the mood
stabilizer lithium. Interestingly, most of these plastic effects
are disease dependent, while other are lithiumdependent and
most of them are enhanced by the administration of lithium
in disease conditions.This is the case of the increase in nestin-
positive cells around the canal, as well as the increase inNeuN
and 𝛽III-tubulin positive cells.Thus, as shown for spinal cord
trauma, lithium is likely to be a powerful modulator for stem
cell differentiation also in ALS. In summary, in the present
work we found that, in the presence of a chronic spinal cord
disorder (ALS-alike G93A mice), the ependyma-containing
lamina X appears to be enriched of newly proliferating cells
which is reminiscent of what happens following a spinal cord
injury. As described following a spinal cord injury, these cells
appear to differentiate towards a glial phenotype. The most
remarkable plasticity we described here consists in the com-
bined effects of lithium administration in a spinal cord disor-
der. In fact, in these specific conditions lamina X cells appear
as neuron-like cells expressing early and later neuronalmark-
ers along with calbindin-D28K, thus being reminiscent of the
active stem cell niche in the SVZ under the effects of lithium.
These findings shed new light on what Sabelstro¨m et al.
[7] just posed as an apparent limitation of spinal cord stem
cells, that is, the tendency to produce solely a glial phenotype.
In fact these authors, based on data obtained from diseased
spinal cord (mostly traumatic), concluded literally that “the
spinal cord microenvironment appears to have a strong
gliogenic influence and/or fails to support neuronal survival.”
This is in line with what we found in the natural course of
ALS mice without lithium administration. Adding lithium
is likely to address lamina X cells towards neuronal survival
while suppressing the gliogenic influence. Further studies
are needed to dissect the molecular mechanisms underlying
the phenomena we formally described in the present paper.
Moreover, beyond antigen expression, it is important to verify
whether the effects of lithium on the ALS spinal cord produce
electrophysiological effects which substantiate the neuronal
phenotype. Finally it would be worthy to investigate the fate
of the neuron-like cells. Do they synaptically integrate in the
spinal cord under disease? Do they represent a paracrine
source of active cytokines? Or do they merely represent an
inert biological entity? We like to finish the conclusions with
these big open questions.
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